MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?
NCT03618212 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2021-08-09
Summary
The investigators wish to determine which anatomic regions need to be explored in order to correctly diagnose myeloma: whether axial skeletal MRI alone is sufficient or whether it is necessary to perform a total skeletal MRI.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
MRI
Skeletal MRI and pelvic and spinal MRI
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Nīmes
lead OTHER
Principal Investigators
-
Ahmed Larbi, MD · CHU Nimes
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-21
- Primary Completion
- 2020-03-31
- Completion
- 2020-03-31
Countries
- France
Study Locations
More Related Trials
-
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
NCT06182774 ·Status: RECRUITING ·Phase: PHASE3
-
Non-invasive MRD Assessment in Multiple Myeloma
NCT05625971 ·Status: COMPLETED
-
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
NCT00305812 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients
NCT06457464 ·Status: NOT_YET_RECRUITING
-
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
NCT02997813 ·Status: COMPLETED
-
Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone
NCT03375567 ·Status: COMPLETED ·Phase: NA
-
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
NCT05477797 ·Status: RECRUITING ·Phase: NA
-
Etiology of Multiple Myeloma: A Case-Control Study
NCT00505999 ·Status: UNKNOWN
-
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
NCT00405756 ·Status: COMPLETED ·Phase: PHASE3
-
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
NCT05001087 ·Status: RECRUITING
-
MYeloma Resistance And Clonal Evolution
NCT03807128 ·Status: RECRUITING
-
Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) Patients
NCT05428163 ·Status: COMPLETED
-
Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression
NCT04872023 ·Status: COMPLETED ·Phase: NA
-
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
NCT00567229 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
NCT02800954 ·Status: COMPLETED ·Phase: NA
-
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512 ·Status: ACTIVE_NOT_RECRUITING
-
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
NCT03742297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
NCT01208766 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
NCT01237249 ·Status: COMPLETED ·Phase: PHASE2
-
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma
NCT00800059 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients
NCT01160107 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Optimization in Patients With Untreated Multiple Myeloma
NCT02145598 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
NCT04892264 ·Status: TERMINATED ·Phase: PHASE1
-
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
NCT06212323 ·Status: RECRUITING